Literature DB >> 17895325

The age-associated decline of androgens in reproductive age and menopausal Black and White women.

Jessica B Spencer1, Mitchel Klein, Ashim Kumar, Ricardo Azziz.   

Abstract

CONTEXT: The effect of race and obesity on the age-associated decline of androgens in reproductive-aged and menopausal women has not been well characterized.
OBJECTIVE: Our objective was to determine the impact of racial differences and body mass index (BMI) on the change in androgen levels during a woman's reproductive and early menopausal years. DESIGN AND
SETTING: We conducted a frequency-matched cross-sectional study at a tertiary academic medical center. PATIENTS OR OTHER PARTICIPANTS: Subjects included 260 healthy, nonhirsute and eumenorrheic, self-identified Black and White women, ages 15-60 yr.
INTERVENTIONS: A medical and reproductive history, physical exam, and blood sampling were determined in the fasting state during the early follicular phase. MAIN OUTCOME MEASURES: Serum levels of androgens or androgen metabolites (dehydroepiandrosterone sulfate, androstenedione, and total and free testosterone) and SHBG were measured and the BMI, the waist-to-hip ratio (WHR), and the basal insulin resistance estimated by the homeostasis model assessment for insulin resistance determined.
RESULTS: After controlling for differences in BMI, insulin resistance, and WHR, Black women had lower androgen levels than age-matched White women. All androgens, or androgen metabolites, declined similarly across the reproductive lifespan and menopausal transition in both Black and White women. Race was a significant predictor of dehydroepiandrosterone sulfate, androstenedione, and total and free testosterone but not SHBG.
CONCLUSIONS: Eumenorrheic, nonhirsute Black women have a lower range of normal androgen levels than White women of the same age, BMI, WHR, and homeostasis model assessment index for insulin resistance. Race and age-adjusted data should be considered when evaluating androgen levels in women between the ages of 15 and 60 yr.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895325     DOI: 10.1210/jc.2006-2365

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry.

Authors:  Micol S Rothman; Nichole E Carlson; Mei Xu; Christina Wang; Ronald Swerdloff; Paul Lee; Victor H H Goh; E Chester Ridgway; Margaret E Wierman
Journal:  Steroids       Date:  2010-11-09       Impact factor: 2.668

2.  Bioavailable Testosterone Linearly Declines Over A Wide Age Spectrum in Men and Women From The Baltimore Longitudinal Study of Aging.

Authors:  Elisa Fabbri; Yang An; Marta Gonzalez-Freire; Marco Zoli; Marcello Maggio; Stephanie A Studenski; Josephine M Egan; Chee W Chia; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-02-27       Impact factor: 6.053

3.  An exploration of secondary sex ratios among women diagnosed with anxiety disorders.

Authors:  M S Subbaraman; S J Goldman-Mellor; E S Anderson; K Z Lewinn; K B Saxton; M Shumway; R Catalano
Journal:  Hum Reprod       Date:  2010-06-22       Impact factor: 6.918

4.  Androgen Receptor Coregulator CTBP1-AS Is Associated With Polycystic Ovary Syndrome in Chinese Women: A Preliminary Study.

Authors:  Zhenteng Liu; Cuifang Hao; Dehua Song; Ning Zhang; Hongchu Bao; Qinglan Qu
Journal:  Reprod Sci       Date:  2014-12-31       Impact factor: 3.060

5.  Menopausal transition stage-specific changes in circulating adrenal androgens.

Authors:  Daniel S McConnell; Frank Z Stanczyk; Maryfran R Sowers; John F Randolph; Bill L Lasley
Journal:  Menopause       Date:  2012-06       Impact factor: 2.953

6.  Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome.

Authors:  Ricardo Azziz; Wendy Y Chang; Frank Z Stanczyk; Keslie Woods
Journal:  Fertil Steril       Date:  2012-10-31       Impact factor: 7.329

7.  Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison.

Authors:  Jos Bloemers; Kim van Rooij; Leo de Leede; Henderik W Frijlink; Hans P F Koppeschaar; Berend Olivier; Adriaan Tuiten
Journal:  Br J Clin Pharmacol       Date:  2016-03-07       Impact factor: 4.335

8.  Screening for Androgen Excess in Women: Accuracy of Self-Reported Excess Body Hair Growth and Menstrual Dysfunction.

Authors:  Jessica L Chan; Marita Pall; Uche Ezeh; Ruchi Mathur; Margareta D Pisarska; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

9.  Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Lisa L Kahle; Louise A Brinton
Journal:  Breast Cancer Res       Date:  2010-11-18       Impact factor: 6.466

10.  Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies.

Authors:  T J Key; P N Appleby; G K Reeves; A W Roddam; K J Helzlsouer; A J Alberg; D E Rollison; J F Dorgan; L A Brinton; K Overvad; R Kaaks; A Trichopoulou; F Clavel-Chapelon; S Panico; E J Duell; P H M Peeters; S Rinaldi; I S Fentiman; M Dowsett; J Manjer; P Lenner; G Hallmans; L Baglietto; D R English; G G Giles; J L Hopper; G Severi; H A Morris; S E Hankinson; S S Tworoger; K Koenig; A Zeleniuch-Jacquotte; A A Arslan; P Toniolo; R E Shore; V Krogh; A Micheli; F Berrino; E Barrett-Connor; G A Laughlin; M Kabuto; S Akiba; R G Stevens; K Neriishi; C E Land; J A Cauley; Li Yung Lui; Steven R Cummings; M J Gunter; T E Rohan; H D Strickler
Journal:  Br J Cancer       Date:  2011-07-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.